Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION) (MOTION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05217849
Recruitment Status : Recruiting
First Posted : February 1, 2022
Last Update Posted : March 8, 2022
Sponsor:
Collaborators:
San Francisco VA Health Care System
University of California, Los Angeles
United States Department of Defense
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
The purpose of this study is to compare the effects of three on-line wellness interventions for improving physical and cognitive function and brain connectivity in adults who are at least 55 years old and are experiencing symptoms of memory and/or cognitive difficulties.

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Subjective Memory Decline Behavioral: Tai Chi Behavioral: Preventing Loss of Independence through Exercise (PLIE) Behavioral: Health and Wellness Education Not Applicable

Detailed Description:
The proposed study will perform a randomized, controlled trial (RCT) to compare the effects of three on-line wellness interventions for adults (age 55 years and older) who are experiencing memory and/or cognitive decline. Study participants will be randomly assigned to one of three on-line wellness interventions: (a) Tai Chi, (b) mindful movement course, or (c) health and wellness education course. All interventions will be one hour long, held on-line twice a week for 12 weeks. The co-primary outcomes are 3-month change in cognitive function (Alzheimer's Disease Assessment Scale - cognitive subscale, ADAS-cog) and functional brain connectivity within the default mode network (DMN). Secondary behavioral outcomes will include measures of specific cognitive processes (e.g., auditory memory, executive function, processing speed), physical function (e.g., mobility), anxiety, depression, fatigue, pain, sleep quality, social activities/social isolation, and quality of life. Secondary neuroimaging outcomes will include measures of functional connectivity in other intrinsic brain networks (e.g., salience, central executive, language), cerebral perfusion, and structural white matter integrity. The behavioral and imaging outcomes will be assessed at baseline and upon completion of the 12-week interventions. To assess durability of the behavioral effects of the interventions, the cognitive and behavioral outcomes will be assessed again 6 months after the completion of the interventions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomly assigned to an on-line Tai Chi class, an on-line mindful movement class, or to an on-line Health and Wellness Education classes. All classes will meet twice a week for one hour for 12-weeks. The randomization sequence will be generated in advance by Dr. Chao's research team using a random number generator and will be maintained in a secure location. Individuals who collect and analyze outcome data will be blinded to group assignment.
Masking: Single (Outcomes Assessor)
Masking Description: The randomization sequence will be generated in advance by Dr. Chao's research team using a random number generator and will be maintained in a secure location. Individuals who collect or analyze outcome data will be blinded to group assignment.
Primary Purpose: Treatment
Official Title: Multi-domain Online Therapeutic Investigation Of Neurocognition
Actual Study Start Date : February 15, 2022
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : June 30, 2026

Arm Intervention/treatment
Experimental: Tai Chi
Participants will engage in 60-minute Tai Chi classes twice a week for 12 weeks. The classes will be live-streamed over the internet. Tai Chi is an ancient Chinese system of gentle physical exercise and stretching. It involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
Behavioral: Tai Chi
Tai Chi is an ancient Chinese form of exercise/martial art that involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
Other Name: Tai-Chi-Chih (TCC)

Experimental: Gentle, Mindful Movement
Participants will engage in a gentle, mindful movement class twice a week for 12 weeks. The classes will be one hour long and will be live-streamed over the internet. The mindful movement classes will combine elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
Behavioral: Preventing Loss of Independence through Exercise (PLIE)
PLIE is a gentle, mindful movement exercise program that integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection.
Other Name: gentle, mindful movement class

Active Comparator: Health and Wellness Education
Participants will engage in bi-weekly 60 minute sessions of Health and Wellness Education classes. The classes will be held on-line for 12 weeks.
Behavioral: Health and Wellness Education
This on-line class will consist of hour-long lectures/talks about various topics related to healthy aging and wellness.




Primary Outcome Measures :
  1. Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Scores [ Time Frame: Change from baseline to 1-week post-treatment. ]
    The Alzheimer's Disease Assessment Scale-Cognitive Subscale is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. ADAS-cog scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment.

  2. Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Scores [ Time Frame: Change from baseline to 6 months after treatment ends. ]
    The Alzheimer's Disease Assessment Scale-Cognitive Subscale is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. ADAS-cog scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment.

  3. Change in Default Mode Network (DMN) functional connectivity [ Time Frame: Change from baseline to 1-week post-treatment. ]

    The default mode network (DMN) is a system of connected brain areas that show increased activity when a person is not focused on what is happening around them. Instead, the DMN is especially active when a person is engaged in introspective activities (e.g., daydreaming, or contemplating the past or future). Research suggests that the DMN is disrupted in people with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD).

    Functional connectivity can be defined as the similarity between brain signals that arise from two anatomically separated brain regions. Similarity between the brain signals can be analyzed using Pearson's correlation.



Secondary Outcome Measures :
  1. Change in Auditory Memory scores [ Time Frame: Change from baseline to 1 week post-treatment. ]
    The stories subtest of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) will be used to assess auditory memory. Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores were then averaged to produce a composite scores. Higher scores are indicative of better performance.

  2. Change in Auditory Memory scores [ Time Frame: Change from baseline to 6 months after treatment ends. ]
    The stories subtest of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) will be used to assess auditory memory. Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores were then averaged to produce a composite scores. Higher scores are indicative of better performance.

  3. Change in Attention/Executive Function Cognitive Domain Scores [ Time Frame: Change from baseline to 1-week post-treatment. ]

    Neuropsychological tests will included the following domains: Attention/Executive Function (Trail Making Test A and B, Stroop Interference [Golden version])

    Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores will be averaged to produce composite scores. Higher scores are indicative of better performance.


  4. Change in Attention/Executive Function Cognitive Domain Scores [ Time Frame: Change from baseline to 6 months after treatment ends. ]

    Neuropsychological tests will included the following domains: Attention/Executive Function (Trail Making Test A and B, Stroop Interference [Golden version])

    Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores will be averaged to produce composite scores. Higher scores are indicative of better performance.


  5. Change in Verbal Fluency scores [ Time Frame: Change from baseline to 1-week post-treatment. ]
    Controlled Oral Word Association test (FAS). Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. Higher scores are indicative of better performance.

  6. Change in Verbal Fluency scores [ Time Frame: Change from baseline to 6 months after treatment ends. ]
    Controlled Oral Word Association test (FAS). Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. Higher scores are indicative of better performance.

  7. Change in Processing Speed Scores [ Time Frame: Change from baseline to 1-week post-treatment. ]
    Processing speed will be assessed with the coding subtest of RBANS as well as the Digit Symbol Substitution Test (DSST). Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores will be averaged to produce composite scores. Higher scores are indicative of better performance.

  8. Change in Processing Speed Scores [ Time Frame: Change from baseline to 6 months after treatment ends. ]
    Processing speed will be assessed with the coding subtest of RBANS as well as the Digit Symbol Substitution Test (DSST). Raw scores will be transformed to z-scores (with a mean of 0 and standard deviation of 1) for each test score of interest across all participants. Thus the sample mean (across all arms) is zero for each test score. The z-scores will be averaged to produce composite scores. Higher scores are indicative of better performance.

  9. Change in Mobility [ Time Frame: Change from baseline to 1-week post-treatment. ]
    Mobility will be assessed with the Timed Up and Go (TUG) test, which assesses the time it takes participants to stand up from a chair, walk 3 meters, turn around, walk back to the chair and sit down. In addition, we will assess steady-state gait during 90 seconds of continuous over-ground walking at normal preferred speed, with and without the addition of a dual task challenge (counting backward by one or by two).

  10. Change in Mobility [ Time Frame: Change from baseline to 6 months after treatment ends. ]
    Mobility will be assessed with the Timed Up and Go (TUG) test, which assesses the time it takes participants to stand up from a chair, walk 3 meters, turn around, walk back to the chair and sit down. In addition, we will assess steady-state gait during 90 seconds of continuous over-ground walking at normal preferred speed, with and without the addition of a dual task challenge (counting backward by one or by two).

  11. Change in Salience Network functional connectivity [ Time Frame: Change from baseline to 1-week post-treatment. ]
    The Salience Network consists of a network of brain regions whose cortical hubs are the anterior cingulate and ventral anterior insular (i.e., frontoinsular) cortices. This network also includes nodes in the amygdala, hypothalamus, ventral striatum, thalamus, and specific brainstem nuclei.

  12. Change in Language Network functional connectivity [ Time Frame: Change from baseline to 1-week post-treatment. ]
    The Language Network consists of a group of left-lateralized frontal and temporal brain regions that responds to written/spoken/signed words and sentences, but not to mental arithmetic, music perception, executive function tasks, or action/gesture perception.


Other Outcome Measures:
  1. Change in PROMIS-29 Health-Related Quality of Life (HRQoL) Domains [ Time Frame: Change from baseline to 1 week post-treatment. ]
    The PROMIS-29 includes seven HRQoL domains: Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain). The pain domain has two subdomains (interference and intensity). Each of the 7 domains has four 5-level items (i.e., 16 decrements each). In addition to these items, pain intensity is assessed using a single 11-point numeric rating scale anchored between no pain (0) and worse imaginable pain (10), adding 10 additional decrements.

  2. Change in PROMIS-29 Health-Related Quality of Life (HRQoL) Domains [ Time Frame: Change from baseline to 6 months after treatment ends. ]
    The PROMIS-29 includes seven HRQoL domains: Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain). The pain domain has two subdomains (interference and intensity). Each of the 7 domains has four 5-level items (i.e., 16 decrements each). In addition to these items, pain intensity is assessed using a single 11-point numeric rating scale anchored between no pain (0) and worse imaginable pain (10), adding 10 additional decrements.

  3. Change in measures of body awareness [ Time Frame: Change from baseline to 1-week post-treatment. ]
    We will examine 3 measures of body awareness: Interoceptive attention is the ability to sustain and control attention to body sensations. Interoceptive self-regulation is the ability to regulate distress by attention to body sensations. These two measures will be assessed with MAIA-2 self-report questionnaire. We will also utilize the Body Awareness portion of the Body Experience Questionnaire to measure interoceptive attention/awareness.

  4. Change in measures of body awareness [ Time Frame: Change from baseline to 6 months after treatment ends. ]
    We will examine 3 measures of body awareness: Interoceptive attention is the ability to sustain and control attention to body sensations. Interoceptive self-regulation is the ability to regulate distress by attention to body sensations. These two measures will be assessed with MAIA-2 self-report questionnaire. We will also utilize the Body Awareness portion of the Body Experience Questionnaire to measure interoceptive attention/awareness.

  5. Change in a measure of mindfulness [ Time Frame: Change from baseline to 1-week post-treatment. ]
    Mindfulness will be assessed with the Freiburg Mindfulness Index (FMI), a valid and reliable 30-item questionnaire measuring mindfulness.

  6. Change in a measure of mindfulness [ Time Frame: Change from baseline to 6 months after treatment ends. ]
    Mindfulness will be assessed with the Freiburg Mindfulness Index (FMI), a valid and reliable 30-item questionnaire measuring mindfulness.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age ≥ 55 years
  • subjective cognitive complaints, defined as self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event
  • Montreal Cognitive Assessment (MoCA) score suggestive of Mild Cognitive Impairment (MCI) status (i.e., < 26)
  • English language fluency
  • Wireless internet connection at home
  • Willingness to travel to the San Francisco VA in northern California or UCLA in southern California for in-person assessments at baseline, after the 12-week interventions, and at the 36-week follow-up
  • Capacity to provide informed consent or legally authorized representative consent and participant assent.

Exclusion Criteria:

  • current or past Axis I psychiatric disorders, or recent unstable medical or neurological disorders
  • disabilities that prevent participation in on-line movement classes (e.g., primarily use wheel-chair, severe visual impairment that would limit ability to observe instructor's movement on screen or severe hearing impairment that would limit ability to hear instructor's directions)
  • insufficient English proficiency
  • limited life expectancy (i.e., enrolled in hospice, metastatic cancer)
  • plan to travel for > 1 week during 12-week intervention period
  • diagnosis of dementia per the DSM-5
  • MoCA score suggestive of dementia (i.e., <17)
  • started dementia medication (cholinesterase inhibitor or memantine) in past 3 months or plans to start dementia medication during study period
  • planning to start/change any psychoactive medication during study period
  • current participation in another research study
  • contraindications to magnetic resonance imaging (MRI), including claustrophobia severe enough to prevent MRI examination, presence of ferrometallic objects in the body that would interfere with MRI examination and/or cause a safety risk (e.g., pacemakers, implanted stimulators, pumps)
  • prior or current training in with Tai Chi, PLIE, or other mind-body practices

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05217849


Contacts
Layout table for location contacts
Contact: Sarah L. Slain, MSc 415-910-1655 Sarah.Slain2@ucsf.edu
Contact: Courtney Sheen, MA 310-794-9523 CSheen@mednet.ucla.edu

Locations
Layout table for location information
United States, California
VA Health Care System Recruiting
San Francisco, California, United States, 94121
Contact: Linda L Chao, PhD    415-221-4810 ext 24386    linda.chao@ucsf.edu   
Sponsors and Collaborators
University of California, San Francisco
San Francisco VA Health Care System
University of California, Los Angeles
United States Department of Defense
Investigators
Layout table for investigator information
Principal Investigator: Linda L Chao, PhD University of California, San Francisco & SFVAHCS
Layout table for additonal information
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT05217849    
Other Study ID Numbers: 21-33507
First Posted: February 1, 2022    Key Record Dates
Last Update Posted: March 8, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders